Monday, May 9, 2016
Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as chief operating officer. In this role, Ros will be responsible for directing and operationalizing Epizyme’s launch readiness efforts for tazemetostat, and will report to Epizyme’s president and chief executive officer, Robert Bazemore.
Formula Pharmaceuticals has appointed Dr. Malcolm K. Brenner, founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, as a member of its Scientific Advisory Board (SAB). The SAB serves as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer (C.I.K.) cells targeting cancer and autoimmune disease.
CROMSOURCE, an international CRO providing a comprehensive portfolio of services to the pharmaceutical, biotechnology and medical device industries, has appointed four senior executives to its management team. The appointments include Dr. Troy W. McCall as chief operating officer (COO), Debbie Kent as global head of TalentSource staffing solutions, Dr. Kerry Dyson as global head of Clinical Research Division and April McCall as vice president of Commercial Operations. Additionally, CROMSOURCE announced the expansion of its North American presence with the opening of an office in Research Triangle Park in North Carolina.
PRA Health Sciences has been recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this recognition. In 2015 PRA was also named the Best International Clinical Company of the Year.
Valeant Pharmaceuticals International has named Joseph C. Papa to become Valeant’s chairman and chief executive officer. Papa is expected to join Valeant by early May. Papa will join Valeant from Perrigo company, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as chairman and chief executive officer. Papa, who will also join Valeant’s board of directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a director until Papa arrives at Valeant.
Quintiles, a provider of biopharmaceutical services, has been named to the 2016 CSO50 by IDG’s CSO magazine. This award recognizes the company’s innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company’s fourth consecutive year receiving the security award.